Paris, France, and New York, USA, October 25, 2017 – Medicen Paris Region, Europe’s leading healthcare cluster, will partner with Business France for the third year in a row for the MedStartUp event in New York. The cluster will bring a delegation of ten members along with seven of the eleven companies nominated for the Galien – MedStartUp awards.

The event, which will take place on October 25 and 26 in New York, will connect more than 250 US private and public representatives with 48 French start-ups selected for their innovative solutions in healthcare. Among these companies will be ten members of Medicen Paris Region, representing the diversity of life science companies in the Ile de France region: Acticor Biotech, Allcare, Bioserenity, Biotrial, Cardiawave, Damae Medical, H4D, myBrain Technologies, Osseomatrix and Sparing Vision.

The MedStartUp event developed from the close partnership between Business France and the US-based Galien Foundation. It allows French companies to meet US and Canadian representatives of the pharmaceutical industry, the medtech and e-health sectors, also insurers, patient organizations, academics and investors.

The MedStartUp program encourages and rewards innovative collaborative projects. It is a stepping stone for French start-ups wishing to enter the North American market. For the 2017 edition, existing Franco-Israeli partnerships will also have access to the event to develop strong collaborations between these three countries, which are internationally recognized for their innovation in healthcare.

Thanks to the experience gained during the two previous editions, this year sees seven of Medicen Paris Region’s members among the eleven companies selected (from the 25 projects initially submitted) for the Galien – MedStartUp awards. Each will present its Franco-American project in front of a prestigious jury chaired by Bernard Poussot, director of Roche Holding and former CEO of WYETH:

  • Roch DOLIVEUX – Honorary CEO, UCB
  • Mikael DOLSTEN – Global R&D president, Pfizer
  • Jean-Pierre GARNIER – Former CEO, GSK
  • Franz HUMER – Former CEO, Roche
  • François MAISONROUGE – Senior managing director, Evercore Partners
  • Paul STOFFELS – Chief scientific officer, Johnson and Johnson
  • Elias ZERHOUNI – Global R&D president, Sanofi

The nominated companies from Medicen are:

The four winners of the 2017 Galien – MedStartUp awards – one per category – will be unveiled during an official ceremony on October 26 at the Alexandria Life Sciences Center in New York. Each will receive a $25,000 (€21,200) prize from the Galien Foundation and six months support from Business France. Each of them will then be supported for 6 months by the Healthcare team of Business France in the implementation of their partnership and business development in North America.

“We are very pleased with this partnership, established three years ago. In addition to the quality of the program and the impact for our companies, this will give us the opportunity to show the long-term commitment of our international strategy. The fact that our companies are increasingly present among the nominees for the MedStartUp awards underlines the diversity and quality of the Ile de France region ecosystem,” said Béatrice Falise-Mirat, CEO of Medicen Paris Region.


About Medicen Paris Region

Medicen Paris Region is a competitiveness cluster for innovative health technologies, with national and international scope. With more than 300 companies, research centers, universities, hospitals and local authorities as members, it aims to position the Paris region as Europe’s leading healthcare cluster. It focuses on five strategic areas: biological diagnostics, diagnostic and interventional imaging, regenerative medicine and biomaterials, digital health and translational medicine. In close collaboration with local, regional and national healthcare innovation players, Medicen Paris Region aims to:

  • Foster the emergence, development and funding of certified collaborative projects in the healthcare sector, in order to create economic value and jobs
  • Increase the international development of innovative startups and SMEs
  • Strengthen the attractiveness of the Paris region, which represents more than 50% of life sciences activity in France

Since the creation of the cluster in 2005, 62 innovative products have been launched in the imaging, medical devices and biological tools sectors. The cluster has certified 292 projects. They received funding from the French government (French Inter-Ministry Fund FUI, Structuring Projects fund), the public investment bank Bpifrance, the National Research Agency, the European Regional Development Fund, the Investments for the Future program and/or local authorities, and the Paris region. Total investment is close to €1.9 billion and €533 million of public aid.


About Business France

Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France.

It promotes France’s companies, business image and national attractiveness as an investment location. It also runs the VIE international internship program.

Founded in 2015 through the merger of UBIFRANCE and the Invest in France Agency, Business France has 1,500 personnel, both in France and in 70 countries throughout the world, who work with a network of public- and private-sector partners. 


About the Galien Foundation

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve human health. Its vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.